Collecting Duct Carcinoma: Characteristics and Survival Outcomes From UroCCR Database (CDCSurv UroCCR n°141)

IF 2.3 3区医学 Q3 ONCOLOGY

Clinical genitourinary cancer Pub Date : 2025-01-23 DOI:10.1016/j.clgc.2025.102305

Louis-Pacôme Le Mével , Jean-Christophe Bernhard , Mokrane Yacoub , Thibaut Waeckel , Céline Bazille , Cécile Champy , Maria Mamodaly , Karim Bensalah , Nathalie Rioux-Leclercq , Constance Michel , Ilhem Hergli , Louis Surlemont , Julie Leclerc , Morgan Roupret , Franck Bruyere , Gaëlle Fromont , Thibaut Tricard , Véronique Lindner , Bastien PARIER , Sophie Ferlicot , Pierre Bigot

{"title":"Collecting Duct Carcinoma: Characteristics and Survival Outcomes From UroCCR Database (CDCSurv UroCCR n°141)","authors":"Louis-Pacôme Le Mével , Jean-Christophe Bernhard , Mokrane Yacoub , Thibaut Waeckel , Céline Bazille , Cécile Champy , Maria Mamodaly , Karim Bensalah , Nathalie Rioux-Leclercq , Constance Michel , Ilhem Hergli , Louis Surlemont , Julie Leclerc , Morgan Roupret , Franck Bruyere , Gaëlle Fromont , Thibaut Tricard , Véronique Lindner , Bastien PARIER , Sophie Ferlicot , Pierre Bigot","doi":"10.1016/j.clgc.2025.102305","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>To describe characteristics and survival outcomes of patients with renal collecting duct carcinoma (RCDC).</div></div><div><h3>Methods</h3><div>We retrospectively analyzed data from patients treated for RCDC and included in the UroCCR database between 2007 and 2023. All tumors had a centralized pathological review by a CARARE network pathologist. Oncologic outcomes for cancer-specific survival (CSS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method.</div></div><div><h3>Results</h3><div>A total of 29 patients with RCDC were included. The prevalence of RCDC in the UroCCR database was 0.18% (29/16133). The median age was 63 years (45-81). At diagnosis, 20 (69%) patients were symptomatic and 9 (31%) had a metastatic disease. Partial and radical nephrectomy were performed in respectively 8 (29.6%) and 19 (70.4%) cases. The median CSS were 21 months (95% CI 9.6-32) and median PFS was 7 months (95% CI 3.6-10.3). In the nonmetastatic group, the median CSS was 22 months (95% CI: 6.2-37), and median PFS was 12 months (95% CI: 0-39). Two years estimated PFS and CSS rates were respectively 29.7% and 38%. A localized disease (<em>P</em> = .012) and a tumor size inferior to 4 cm (<em>P</em> = .045) were associated with better oncological outcomes.</div></div><div><h3>Conclusion</h3><div>RCDC is a rare cancer with poor prognosis, and no treatment has demonstrated a significant improvement in survival. Recurrences are frequent and early. Management is heterogeneous and ineffective. These outcomes reinforce the need to better understand this tumor and evaluate alternative treatments.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 2","pages":"Article 102305"},"PeriodicalIF":2.3000,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical genitourinary cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1558767325000072","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

To describe characteristics and survival outcomes of patients with renal collecting duct carcinoma (RCDC).

Methods

We retrospectively analyzed data from patients treated for RCDC and included in the UroCCR database between 2007 and 2023. All tumors had a centralized pathological review by a CARARE network pathologist. Oncologic outcomes for cancer-specific survival (CSS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method.

Results

A total of 29 patients with RCDC were included. The prevalence of RCDC in the UroCCR database was 0.18% (29/16133). The median age was 63 years (45-81). At diagnosis, 20 (69%) patients were symptomatic and 9 (31%) had a metastatic disease. Partial and radical nephrectomy were performed in respectively 8 (29.6%) and 19 (70.4%) cases. The median CSS were 21 months (95% CI 9.6-32) and median PFS was 7 months (95% CI 3.6-10.3). In the nonmetastatic group, the median CSS was 22 months (95% CI: 6.2-37), and median PFS was 12 months (95% CI: 0-39). Two years estimated PFS and CSS rates were respectively 29.7% and 38%. A localized disease (P = .012) and a tumor size inferior to 4 cm (P = .045) were associated with better oncological outcomes.

Conclusion

RCDC is a rare cancer with poor prognosis, and no treatment has demonstrated a significant improvement in survival. Recurrences are frequent and early. Management is heterogeneous and ineffective. These outcomes reinforce the need to better understand this tumor and evaluate alternative treatments.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical genitourinary cancer 医学-泌尿学与肾脏学

CiteScore

5.20

自引率

6.20%

发文量

201

审稿时长

54 days

期刊介绍： Clinical Genitourinary Cancer is a peer-reviewed journal that publishes original articles describing various aspects of clinical and translational research in genitourinary cancers. Clinical Genitourinary Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of genitourinary cancers. The main emphasis is on recent scientific developments in all areas related to genitourinary malignancies. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.